Insider Transactions: DBV Technologies And 2 Other Stocks Under $2 Recent Insider Transactions: A Glimpse into Penny Stocks

Avatar photo



The Dow Jones index closed higher by around 50 points on Thursday. Insider transactions provide a window into the confidence or concern about a company’s prospects. For investors and traders eyeing penny stocks, these transactions can be a valuable factor in their decision-making process.


Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.


Insider Trades Uncovered:


  • The Scoop: Dalrada Financial Corporation DFCO Chief Executive Officer Brian Bonar snapped up 52,600 shares at an average price of $0.22, amounting to an $11,831 investment.
  • What’s Up: The company’s stock skidded approximately 16% over the past month.
  • What Dalrada Financial Is About: Dalrada Financial Corp, headquartered in the United States, offers financial, insurance, benefit, and business process outsourcing products and services to companies.


Research Frontiers


  • The Deal: Research Frontiers Incorporated REFR Director Darryl Daigle purchased a total of 1,000 shares at an average price of $1.00, amounting to a $1,000 stake.
  • What’s the Buzz: On Nov. 2, Research Frontiers reported a narrower third-quarter loss.
  • What Research Frontiers Engages In: Research Frontiers Inc is involved in the development and marketing of technology and devices to control the flow of light.


Check This Out: Investor Sentiment Edges Higher As S&P 500 Briefly Breaches 5,000 Level


DBV Technologies


  • The Trade: DBV Technologies S.A. DBVT Director Adora Ndu acquired a total of 1,825 shares at an average price of $0.89. Ndu spent around $1,624 to acquire these shares.
  • What’s the Latest: On Nov. 10, DBV Technologies announced 2-year results from ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ peanut in toddlers.
  • What DBV Technologies Is All About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.


Don’t forget to check out our premarket coverage here


 

 


5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.

The free Daily Market Overview 250k traders and investors are reading

Read Now